Twinlab Consolidated Holdings, Inc.

Twinlab Consolidated Holdings, Inc.

TLCC
Twinlab Consolidated Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
103,637.00Market Cap
Twinlab Consolidated Holdings, Inc.
TLCC
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
0.38
0.29
0.34
0.33
0.34
0.29
0.29
0.26
0.28
0.07
0.05
- -
0.05
Revenue per Share
- -
-0.01
-0.1
-0.15
- -
-0.12
-0.08
-0.17
-0.06
-0.06
-0.03
-0.05
- -
-0.06
Basic EPS, GAAP
- -
0.01
-0.07
-0.02
-0.1
-0.03
-0.03
-0.03
-0.02
0.01
-0.02
0.01
- -
0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.83
-0.88
-0.93
-0.86
-1
-1.08
-1.25
-1.29
-1.34
-1.37
-1.43
- -
-1.44
Book Value per Share
- -
-0.42
-0.06
-0.24
-0.2
-0.27
-0.33
-0.39
-0.44
-0.45
-0.48
-0.54
- -
-0.55
Tangible Book Value per Share
- -
200
213
241
262
253
254
256
257
259
259
259
- -
259
Basic Weighted Avg Shares
- -
76
61
82
86
86
73
73
66
72
17
14
12
13
Sales/Revenue/Turnover
- -
0.25
-19.78
-17.06
-14.32
-11.72
-19.09
-19.55
-8.15
4.75
-8.38
-10.2
-15.23
-6.69
Operating Margin (%)
- -
2
1
1
3
3
3
2
2
1
1
1
1
-1
Depreciation Expense
- -
-2
-21
-36
-1
-29
-20
-45
-14
-15
-8
-14
-9
-16
Net Income, GAAP
- -
- -
- -
- -
348.73
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-3.26
-34.4
-44.58
-0.79
-34.49
-27.85
-60.58
-21.69
-20.72
-47.78
-100.71
-81.43
-122.74
Profit Margin (%)
- -
-65
-1
-47
-4
-68
-70
-102
-115
-119
-127
-140
-150
-144
Working Capital
- -
23
13
13
51
3
15
- -
5
5
3
2
- -
2
LT Debt
- -
-76
-5
- -
2
-27
-44
-88
-102
-117
-125
-139
-149
-143
Total Equity
- -
- -
- -
- -
68.56
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
12.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
95
94
94
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
259
259
259
Market Capitalization
10
2
4

Working Capital

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
6
5
4
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
2
1
1
Inventories
3
4
2
Total Current Liabilities
146
147
148
Payables & Accruals
44
46
47
ST Debt
95
94
94
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-227.02%
11.16%
6.83%
Free Cash Flow
-32.24%
-148.13%
-109.49%
Net Income, GAAP
420.02%
-14.55%
-30.74%
Sales/Revenue/Turnover
-8.87%
-22.47%
-14.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
13
14
5
9
17
2023
4
3
4
3
14
2024
3
3
3
- -
12

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
-0.01
-0.01
- -
-0.03
2023
-0.01
-0.02
-0.02
- -
-0.05
2024
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Twinlab Consolidated Holdings, Inc. is a public company primarily engaged in the manufacture, marketing, distribution, and retail of nutritional supplements and natural health products. Founded in 1968 and headquartered in Boca Raton, Florida, the company operates across the United States and internationally. Its core products include vitamins, minerals, specialty supplements such as resveratrol, collagen, and keratin, skincare products, and sports nutrition products marketed under brand names including Twinlab, Reserveage Nutrition, ResVitale, Metabolife, and Alvita. The company offers these products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, powders, and herbal teas. Additionally, Twinlab Consolidated Holdings provides contract manufacturing and private label services through its NutraScience Labs brand. The company has recently restructured its business to focus more intensively on brand development and innovation while expanding its operational capabilities. A notable strategic development includes entering into a manufacturing agreement with Bonne Santé Natural Manufacturing to enhance its critical manufacturing capabilities for global sales initiatives. Twinlab has also strengthened its executive team to drive revenue growth and distribution for its legacy and new brands. This reshaping signifies its commitment to evolving with the natural products market and expanding its footprint in health and wellness sectors. The company embraces direct-to-consumer operations alongside traditional retail channels such as health stores, supermarkets, and online platforms. Twinlab Consolidated Holdings serves health-conscious consumers through its extensive product portfolio that targets dietary supplementation, healthy aging, beauty, energy, and weight management. Its industry presence spans the health and wellness, fitness, and natural products segments. The company continues to leverage acquisitions and strategic partnerships to grow its market share and product offerings in the competitive nutritional supplement industry. Twinlab Consolidated Holdings encompasses several well-established brands and maintains contract manufacturing operations focused on product quality and innovation. The company remains committed to American manufacturing, with production facilities located primarily in the USA. This comprehensive approach to brand management, product innovation, and manufacturing partnerships positions Twinlab Consolidated Holdings as a prominent player in the global nutritional supplements and natural products industry. The company's recent operational enhancements and strategic alliances underline its focus on sustainability and growth in both domestic and international markets. Twinlab Consolidated Holdings is listed on OTC markets under the ticker TLCC. It employs around 200 individuals and continues to pursue growth through product development, market expansion, and operational excellence. This description is based on the latest publicly available information as of late 2025.